Study of serum glucose and cholesterol level in schizophrenic patient’s before and after treatment of olanzapine, risperidone and haloperidol

Autor: Vinod Koshley, Usha Joshi, Ajay Halwai, Rajesh Hishikar, Basant L Maheshwari
Rok vydání: 2020
Předmět:
Zdroj: Indian Journal of Pharmacy and Pharmacology. 5:146-152
ISSN: 2393-9087
2393-9079
DOI: 10.18231/2393-9087.2018.0031
Popis: Objectives: To evaluate the potential association between antipsychotics (Olanzapine, Risperidone and Haloperidol), serum glucose level and serum cholesterol level in schizophrenic patients. Introduction: Schizophrenia is quite prevalent and has high rate of chronicity and morbidity. Newer atypical antipsychotic drugs were developed in response to limitations such as lack of efficacy and side effects associated with older (conventional) agents. However, significant hyperglycemia, dyslipidemia and weight gain have been reported with the use of newer atypical antipsychotics. Materials and Methods: This was an observational prospective study. Total 75 schizophrenic patients were divided in three groups according to treatment allocated (group I- olanzapine, group II- risperidone, group III haloperidol) comprising of 25 patients in each group. Blood sample was collected when patient came to hospital for the first time before starting the treatment and 6 weeks after treatment, then again 6 months after treatment, fasting serum glucose and cholesterol levels were estimated by enzymatic procedure. Simultaneously body weight was also measured. Results: In this study majority of patients were male-73.33% with mean age of 30.76 years. There were significant increase in serum glucose levels and serum cholesterol level, after 6 weeks and 6 months of treatment (t=3.11 p t=3.65 p Conclusion: Olanzapine was associated with increased risk of glucose intolerance, dyslipidemia and weight gain. Keywords: Antipsychotics, Schizophrenia, Cholesterol, Diabetes, Weight gain.
Databáze: OpenAIRE
Externí odkaz: